How do you approach adjuvant therapy in patients who have a poor clinical response to neoadjuvant endocrine therapy?  

Clinical response rates to neoadjuvant endocrine therapy vary from 40-60% in ER-enriched tumors. Pre and post-treatment PEPI score is shown to be prognostic. It is currently unknown what is best to do for women who do not respond well clinically, or for those who have a high ki67 and/or high PEPI s...

While there is little clinical trial experience to support this, I think that it is useful to differentiate between patients with indolent cancers that are unlikely to respond, clinically or pathologically, to either neoadjuvant endocrine therapy - even after 6 months of treatment - o...